Coya Therapeutics to Participate in BTIG Fireside Discussion

Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Dr. Stanley Appel, M.D., Chairman of Coya’s Scientific Advisory Board and Chief Medical Officer Dr. Fred Grossman will participate in a fireside discussion with BTIG analyst Tom Shrader on Wednesday, March 13, 2024, at 12pm ET.

Topics to be discussed include the role of regulatory T cells in treating neurodegenerative diseases, the biomarker (4-HNE) ALS survival data presented today by Dr. Stanley Appel, and Coya’s regulatory pathway for COYA 302, its lead drug candidate that is being explored in Amyotrophic Lateral Sclerosis (ALS), Parkinson’s disease, Frontotemporal disease, and Alzheimer’s disease.

Investors interested in attending this event should contact their respective BTIG representative to be granted access.

About COYA 302

COYA 302 is an investigational and proprietary biologic combination therapy with a dual immunomodulatory mechanism of action intended to enhance the anti-inflammatory function of regulatory T cells (Tregs) and suppress the inflammation produced by activated monocytes and macrophages. COYA 302 is comprised of proprietary low dose interleukin-2 (LD IL-2) and CTLA-4 Ig (abatacept) and is being developed for subcutaneous administration for the treatment of patients with ALS, FTD, PD, and AD. These mechanisms may have additive or synergistic effects.

In February of 2023, Coya announced results from a proof-of-concept, open-label clinical study evaluating commercially available LD IL-2 and CTLA-4 Ig in a small cohort of patients with ALS conducted at the Houston Methodist Research Institute (Houston, Texas) by Stanley Appel, M.D., Jason Thonhoff, M.D., Ph.D., and David Beers, Ph.D.. This study was the first-of-its-kind evaluating this dual-mechanism immunotherapy for the treatment of ALS. Patients in the study received investigational treatment for 48 consecutive weeks and were evaluated for safety and tolerability, Treg function, serum biomarkers of oxidative stress and inflammation, and clinical functioning as measured by the ALSFRS-R scale.